Frapeja Pharma SRL
Frapeja Pharma reported total assets of 772,946 € at the end of the 2025 financial year (annual accounts filed with the NBB on 05 Jun 2026).
The score of Frapeja Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +108 % Total assets -14 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Frapeja Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −37,162 € | ||||
| Equity | 135,972 € | ||||
| Cash | 6,780 € | ||||
| EBITDA | 50,271 € | ||||
| Total assets | 772,946 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 05 Jun 2026
- Year ended 31 Dec 2024filed on 26 May 2025
- Year ended 31 Dec 2023filed on 17 Jul 2024
- Year ended 31 Dec 2022filed on 05 Apr 2023
- Year ended 31 Dec 2021filed on 06 Sep 2022
Frapeja Pharma's financial analysis
- Solvency17.6%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Frapeja Pharma
Frapeja Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0562.774.303
- VAT number
- BE0562774303
- Peppol
- Registered · 0208:0562774303 · as of 12 Nov 2026
- Legal form
- SRL
- Incorporated
- 18 Sep 2014
- Registered office
- 9000 Ghent
- Latest accounts
- 2025 · filed on 05 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Frapeja Pharma (SRL) has been based in Ghent since 2014, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 37,162 € and equity of 135,972 €; its revenue is not published. Its solvency stands at 17.6%, below the median of its sector (44.2%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Frapeja Pharma
Companies in the same business, of comparable size and area, outside its group.
- CBKX Pharma Retail sale of pharmaceutical products Ghent · balance sheet 775,561 €
- Beirnaert-Delagaye Retail sale of pharmaceutical products Ghent · balance sheet 766,047 €
- NDC Pharma Retail sale of pharmaceutical products Hooglede · balance sheet 772,892 €
- Pharmacie Blairvacq Retail sale of pharmaceutical products Waremme · balance sheet 773,237 €
- Pharmacies GOFFIN Retail sale of pharmaceutical products Liège · balance sheet 771,286 €
- Brehophar Retail sale of pharmaceutical products Oostkamp · balance sheet 775,082 €
- Apotheek Kastel Retail sale of pharmaceutical products Kasterlee · balance sheet 770,049 €
- D’hONDT FARMA Retail sale of pharmaceutical products Hamme (Vl.) · balance sheet 776,363 €
Frequently asked questions about Frapeja Pharma
What is the revenue of Frapeja Pharma?
Frapeja Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Frapeja Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0562774303 for Frapeja Pharma, if the company is VAT-registered. Its company number (CBE) is 0562.774.303.
Where is the registered office of Frapeja Pharma?
According to the CBE register, the registered office of Frapeja Pharma is in 9000 Ghent.
What is the equity of Frapeja Pharma?
At the close of the 2025 financial year, the equity of Frapeja Pharma amounts to 135,972 €, a solvency of 17.6% of total assets.
Who manages Frapeja Pharma?
The register lists 2 active mandates at Frapeja Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Frapeja Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →